GlassScriptPhysician profile
Melissa Gleason
NPI 1538341805
$3,018.43
in general payments reported to CMS, 2019-2025
28 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $1,397 · 2023: $366 · 2024: $366 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.55 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,080.00 | 2022 | |
| Astellas Pharma US INC | $391.33 | 2022-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $284.36 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $180.66 | 2021-2022 | |
| Axonics, INC. | $123.26 | 2021 | |
| Organon LLC | $112.33 | 2021-2025 | Nexplanon, Jada System |
| Exeltis, USA INC. | $104.53 | 2021-2025 | Slynd |
| Pacira Pharmaceuticals Incorporated | $82.17 | 2025 | Exparel |
| Myovant Sciences INC. | $79.92 | 2021-2022 | |
| Urovant Sciences INC | $60.54 | 2021-2022 | |
| Shield Therapeutics INC | $60.01 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $58.02 | 2023-2025 | |
| Evofem Biosciences, INC. | $42.12 | 2021 | |
| Hologic Sales and Service, LLC | $37.15 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Bayer Healthcare Pharmaceuticals INC. | $33.87 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $33.17 | 2022 | |
| Kerecis Limited | $32.91 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Lilly USA, LLC | $29.96 | 2024 | Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.17 | 2021-2022 | |
| Medtronic, INC. | $24.91 | 2024 | Interstim |
| Therapeuticsmd, INC. | $24.69 | 2021-2022 | |
| Coopersurgical, INC. | $24.16 | 2024 | Paragard T 380a |
| Ultragenyx Pharmaceutical INC. | $22.38 | 2021 | |
| Exact Sciences Corporation | $17.90 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $15.38 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.45 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $12.32 | 2021 | |
| Agile Therapeutics, INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Gleason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.